PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
32440710-6	2021	ApoD-/-ApoE-/- mice had altered sterol profile in the retina but apparently normal chorioretinal vasculature and function.	Sterols	32-38	apolipoprotein D	Mus musculus	0-4
1537279-3	1992	In these cells, exposure to the synthetic glucocorticoid dexamethasone (DEX) markedly decreases basal as well as 17 beta-estradiol (E2)-induced cell proliferation while causing a maximal 10-fold stimulation of apo-D secretion in the presence or absence of E2.	Dexamethasone	57-70	apolipoprotein D	Mus musculus	210-215
1537279-3	1992	In these cells, exposure to the synthetic glucocorticoid dexamethasone (DEX) markedly decreases basal as well as 17 beta-estradiol (E2)-induced cell proliferation while causing a maximal 10-fold stimulation of apo-D secretion in the presence or absence of E2.	Dexamethasone	72-75	apolipoprotein D	Mus musculus	210-215
32440710-9	2021	Retinal levels of Glut4 and Cd36, the glucose transporter and scavenger receptor, respectively, were increased as well, thus linking APOD to retinal glucose and fatty acid metabolism and suggesting the APOD-OB-Rb-GLUT4/CD36 axis.	Fatty Acids	161-171	apolipoprotein D	Mus musculus	133-137
30630053-0	2019	Apolipoprotein D overexpression alters hepatic prostaglandin and omega fatty acid metabolism during the development of a non-inflammatory hepatic steatosis.	Prostaglandins	47-60	apolipoprotein D	Mus musculus	0-16
30630053-0	2019	Apolipoprotein D overexpression alters hepatic prostaglandin and omega fatty acid metabolism during the development of a non-inflammatory hepatic steatosis.	omega fatty acid	65-81	apolipoprotein D	Mus musculus	0-16
30630053-12	2019	The accumulation of several omega fatty acids species in the transgenic mouse liver suggests that ApoD might bind to a broader range of fatty acids than previously thought.	omega fatty acids	28-45	apolipoprotein D	Mus musculus	98-102
30630053-12	2019	The accumulation of several omega fatty acids species in the transgenic mouse liver suggests that ApoD might bind to a broader range of fatty acids than previously thought.	Fatty Acids	34-45	apolipoprotein D	Mus musculus	98-102
30219096-6	2018	Compared to a control group, combined vitamin C and E administration reduced serum total cholesterol and triglyceride levels by decreasing apo B-48-containing lipoproteins, remodeled HDL particles by reducing phospholipid as well as increasing PON1 and apo D content, and diminished PLTP activity and levels.	Ascorbic Acid	38-47	apolipoprotein D	Mus musculus	253-258
26673204-6	2016	In contrast, ABCA1-specific cholesterol efflux correlated strongly with HDL"s content of APOA1, APOC3, and APOD, but not RBP4 and PLTP.	Cholesterol	28-39	apolipoprotein D	Mus musculus	107-111
27271124-0	2017	Apolipoprotein D Overexpression Protects Against Kainate-Induced Neurotoxicity in Mice.	Kainic Acid	49-56	apolipoprotein D	Mus musculus	0-16
27271124-7	2017	Indeed, we demonstrate that apoD can attenuate intracellular cholesterol content in primary hippocampal neurons and in brain of H-apoD Tg mice.	Cholesterol	61-72	apolipoprotein D	Mus musculus	28-32
27271124-7	2017	Indeed, we demonstrate that apoD can attenuate intracellular cholesterol content in primary hippocampal neurons and in brain of H-apoD Tg mice.	Thioguanine	135-137	apolipoprotein D	Mus musculus	28-32
27271124-7	2017	Indeed, we demonstrate that apoD can attenuate intracellular cholesterol content in primary hippocampal neurons and in brain of H-apoD Tg mice.	Thioguanine	135-137	apolipoprotein D	Mus musculus	130-134
21632073-1	2011	Apolipoprotein D (ApoD) is an atypical apolipoprotein with an incompletely understood function in the regulation of triglyceride and glucose metabolism.	Triglycerides	116-128	apolipoprotein D	Mus musculus	0-16
25868396-11	2015	The lack of ApoD results in an age-enhanced significant reduction in neuronal calcium-dependent functionality markers and signs of early reduction of neuronal numbers in the cortex, thus impinging upon parameters clearly differentiating neurodegenerative conditions from healthy brain aging.	Calcium	78-85	apolipoprotein D	Mus musculus	12-16
26083030-0	2015	Apolipoprotein D Transgenic Mice Develop Hepatic Steatosis through Activation of PPARgamma and Fatty Acid Uptake.	Fatty Acids	95-105	apolipoprotein D	Mus musculus	0-16
23568103-5	2013	More importantly, our results in the HT22 cell line indicate that Apo D protein level increases in a concentration-dependent manner specifically at those H2O2 concentrations that caused oxidative damage and apoptotic cell death.	Hydrogen Peroxide	154-158	apolipoprotein D	Mus musculus	66-71
25548917-0	2014	A Western-fed diet increases plasma HDL and LDL-cholesterol levels in apoD-/- mice.	Cholesterol	48-59	apolipoprotein D	Mus musculus	70-74
25548917-5	2014	ApoD-/- mice had higher HDL-cholesterol levels (61+-13-apoD-/- vs. 52+-10-WT-males; 37+-11-apoD-/- vs. 22+-2 WT-female) than WT mice with sex-specific changes in total plasma levels of cholesterol and other lipids.	Cholesterol	28-39	apolipoprotein D	Mus musculus	0-4
25548917-5	2014	ApoD-/- mice had higher HDL-cholesterol levels (61+-13-apoD-/- vs. 52+-10-WT-males; 37+-11-apoD-/- vs. 22+-2 WT-female) than WT mice with sex-specific changes in total plasma levels of cholesterol and other lipids.	Cholesterol	185-196	apolipoprotein D	Mus musculus	0-4
25548917-8	2014	An in vivo HDL metabolism experiment with isolated Western-fed apoD-/- HDL particles showed that female apoD-/- mice had a 36% decrease in the fractional catabolic rate of HDL cholesteryl ester.	Cholesterol Esters	176-193	apolipoprotein D	Mus musculus	104-108
21632073-1	2011	Apolipoprotein D (ApoD) is an atypical apolipoprotein with an incompletely understood function in the regulation of triglyceride and glucose metabolism.	Triglycerides	116-128	apolipoprotein D	Mus musculus	18-22
21632073-2	2011	We have demonstrated that elevated ApoD production in mice results in improved postprandial triglyceride clearance.	Triglycerides	92-104	apolipoprotein D	Mus musculus	35-39
21632073-14	2011	These findings underscore the importance of ApoD in the regulation of plasma insulin levels and triglyceride metabolism, suggesting that ApoD plays an important role in the pathogenesis of dyslipidemia.	Triglycerides	96-108	apolipoprotein D	Mus musculus	44-48
21632073-14	2011	These findings underscore the importance of ApoD in the regulation of plasma insulin levels and triglyceride metabolism, suggesting that ApoD plays an important role in the pathogenesis of dyslipidemia.	Triglycerides	96-108	apolipoprotein D	Mus musculus	137-141
21237263-9	2011	However, in vivo, inhibiting the basal levels of polyamine production was sufficient to induce expression of apolipoprotein D, a marker of oxidative stress, within white matter tracts.	Polyamines	49-58	apolipoprotein D	Mus musculus	109-125
21463325-1	2011	The lipocalin Apolipoprotein D (ApoD), known to protect the nervous system against oxidative stress (OS) in model organisms, is up-regulated early in the mouse brain in response to the ROS generator paraquat.	ros	185-188	apolipoprotein D	Mus musculus	14-30
21463325-1	2011	The lipocalin Apolipoprotein D (ApoD), known to protect the nervous system against oxidative stress (OS) in model organisms, is up-regulated early in the mouse brain in response to the ROS generator paraquat.	ros	185-188	apolipoprotein D	Mus musculus	32-36
21463325-6	2011	When challenged with paraquat, the absence of ApoD modifies the response of genes mainly related to OS management and myelination.	Paraquat	21-29	apolipoprotein D	Mus musculus	46-50
20848217-5	2011	Antioxidation assays showed that the recombinant BbApoD protein had the capacities to scavenge hydroxyl radicals (>= 240 mug/ml) and to prevent nicking of the supercoiled DNA (>= 100 mug/ml) in vitro, providing a biochemical evidence for antioxidant role of ApoD.	Hydroxyl Radical	95-112	apolipoprotein D	Mus musculus	51-55
20124557-0	2010	A role of apolipoprotein D in triglyceride metabolism.	Triglycerides	30-42	apolipoprotein D	Mus musculus	10-26
20124557-3	2010	Here we characterized apolipoprotein D (apoD) in triglyceride metabolism.	Triglycerides	49-61	apolipoprotein D	Mus musculus	22-38
20124557-3	2010	Here we characterized apolipoprotein D (apoD) in triglyceride metabolism.	Triglycerides	49-61	apolipoprotein D	Mus musculus	40-44
20124557-6	2010	Elevated apoD production, derived from adenovirus-mediated gene transfer, resulted in significant reduction in plasma triglyceride levels in mice.	Triglycerides	118-130	apolipoprotein D	Mus musculus	9-13
20124557-10	2010	Obese mice with elevated apoD production exhibited significantly improved triglyceride profiles, correlating with increased plasma LPL activity and enhanced postprandial fat tolerance.	Triglycerides	74-86	apolipoprotein D	Mus musculus	25-29
20124557-11	2010	ApoD was shown to promote LPL-mediated hydrolysis of VLDL in vitro, correlating with its TG-lowering action in vivo.	Thioguanine	89-91	apolipoprotein D	Mus musculus	0-4
11158250-0	2001	Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy.	Clozapine	0-9	apolipoprotein D	Mus musculus	20-36
17849452-6	2008	The expression of 26 genes was decreased in lung tumors, whereas only two genes, Apolipoprotein D and CYP26b, had their mRNA expression increased by bexarotene.	Bexarotene	149-159	apolipoprotein D	Mus musculus	81-97
17011169-0	2007	Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D.	Clozapine	0-9	apolipoprotein D	Mus musculus	75-91
17011169-0	2007	Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D.	Arachidonic Acid	34-50	apolipoprotein D	Mus musculus	75-91
17011169-3	2007	In order to further explore the role of apoD in mechanisms of clozapine function, we have measured a panel of membrane fatty acids and membrane lipids in brain from drug-treated apoD knock-out mice.	Clozapine	62-71	apolipoprotein D	Mus musculus	40-44
17011169-5	2007	We identified significant differences in the levels of membrane fatty acids in response to clozapine treatment specifically in the brains of apoD knock-out mice, but not wild-type (wt) mice.	Fatty Acids	64-75	apolipoprotein D	Mus musculus	141-145
17011169-5	2007	We identified significant differences in the levels of membrane fatty acids in response to clozapine treatment specifically in the brains of apoD knock-out mice, but not wild-type (wt) mice.	Clozapine	91-100	apolipoprotein D	Mus musculus	141-145
17011169-6	2007	The most striking observations were decreases in the levels of fatty acids related to metabolism of arachidonic acid (AA), which is a known binding partner for apoD.	Fatty Acids	63-74	apolipoprotein D	Mus musculus	160-164
17011169-6	2007	The most striking observations were decreases in the levels of fatty acids related to metabolism of arachidonic acid (AA), which is a known binding partner for apoD.	Arachidonic Acid	100-116	apolipoprotein D	Mus musculus	160-164
17011169-8	2007	We further report increases in LA, eicosadienoic acid and docosahexaenoic acid in apoD knock-out compared to wild-type mice.	eicosa-11,14-dienoic acid	35-53	apolipoprotein D	Mus musculus	82-86
17011169-8	2007	We further report increases in LA, eicosadienoic acid and docosahexaenoic acid in apoD knock-out compared to wild-type mice.	Docosahexaenoic Acids	58-78	apolipoprotein D	Mus musculus	82-86
17011169-9	2007	These findings implicate an important apoD/AA interaction, which may be necessary for clozapine function.	Clozapine	86-95	apolipoprotein D	Mus musculus	38-42
19963028-4	2010	Thus, we decided to use in vitro radioligand binding and autoradiography to measure levels of ionotropic glutamate, some muscarinic and serotonin 2A receptors in the CNS of ApoD(-/-) and isogenic wild-type mice.	Glutamic Acid	105-114	apolipoprotein D	Mus musculus	173-177
15560970-3	2005	Recent findings of an increased expression of apoD in the mouse brain after clozapine treatment suggested a role for apoD in the pharmacological action of clozapine.	Clozapine	76-85	apolipoprotein D	Mus musculus	46-50
15560970-3	2005	Recent findings of an increased expression of apoD in the mouse brain after clozapine treatment suggested a role for apoD in the pharmacological action of clozapine.	Clozapine	155-164	apolipoprotein D	Mus musculus	46-50
15560970-3	2005	Recent findings of an increased expression of apoD in the mouse brain after clozapine treatment suggested a role for apoD in the pharmacological action of clozapine.	Clozapine	155-164	apolipoprotein D	Mus musculus	117-121
11158250-3	2001	Using an automated genomics approach, total gene expression analysis (TOGA), we found an approximately threefold increase in the accumulation of the mRNA encoding apolipoprotein D (apoD) in mouse striatum in response to chronic treatment with clozapine.	Clozapine	243-252	apolipoprotein D	Mus musculus	163-179
11158250-3	2001	Using an automated genomics approach, total gene expression analysis (TOGA), we found an approximately threefold increase in the accumulation of the mRNA encoding apolipoprotein D (apoD) in mouse striatum in response to chronic treatment with clozapine.	Clozapine	243-252	apolipoprotein D	Mus musculus	181-185
11158250-4	2001	While in control animals, apoD is expressed predominantly in astrocytes, in situ hybridization and immunohistochemical studies indicated a substantial increase in apoD expression in neurons of the striatum, globus pallidus and thalamus after 2 weeks of clozapine treatment.	Clozapine	253-262	apolipoprotein D	Mus musculus	163-167
11158250-5	2001	Clozapine-induced increases in apoD expression were also observed in some white matter regions.	Clozapine	0-9	apolipoprotein D	Mus musculus	31-35
11158250-6	2001	These results suggest that apoD is a mediator in the mechanisms of clozapine and thus that deficiencies in aspects of lipid metabolism may be responsible for psychoses.	Clozapine	67-76	apolipoprotein D	Mus musculus	27-31
10679292-0	2000	Apolipoprotein E and apolipoprotein D expression in a murine model of singlet oxygen-induced cerebral stroke.	Singlet Oxygen	70-84	apolipoprotein D	Mus musculus	21-37
9422368-0	1998	Cellular cholesterol storage in the Niemann-Pick disease type C mouse is associated with increased expression and defective processing of apolipoprotein D.	Cholesterol	9-20	apolipoprotein D	Mus musculus	138-154
9422368-1	1998	Apolipoprotein D (apoD), a member of the lipocalin superfamily of ligand transporters, has been implicated in the transport of several small hydrophobic molecules including sterols and steroid hormones.	Sterols	173-180	apolipoprotein D	Mus musculus	0-16
9422368-1	1998	Apolipoprotein D (apoD), a member of the lipocalin superfamily of ligand transporters, has been implicated in the transport of several small hydrophobic molecules including sterols and steroid hormones.	Sterols	173-180	apolipoprotein D	Mus musculus	18-22
9422368-1	1998	Apolipoprotein D (apoD), a member of the lipocalin superfamily of ligand transporters, has been implicated in the transport of several small hydrophobic molecules including sterols and steroid hormones.	Steroids	185-201	apolipoprotein D	Mus musculus	0-16
9422368-1	1998	Apolipoprotein D (apoD), a member of the lipocalin superfamily of ligand transporters, has been implicated in the transport of several small hydrophobic molecules including sterols and steroid hormones.	Steroids	185-201	apolipoprotein D	Mus musculus	18-22
9422368-2	1998	We have previously established that apoD is a secreted protein from cultured mouse astrocytes and that treatment with the oxysterol 25-hydroxycholesterol markedly stimulates apoD release.	oxysterol 25-hydroxycholesterol	122-153	apolipoprotein D	Mus musculus	36-40
9422368-2	1998	We have previously established that apoD is a secreted protein from cultured mouse astrocytes and that treatment with the oxysterol 25-hydroxycholesterol markedly stimulates apoD release.	oxysterol 25-hydroxycholesterol	122-153	apolipoprotein D	Mus musculus	174-178
9422368-8	1998	ApoD was found to be a secreted protein from cultured normal astrocytes and treatment with the oxysterol, 25-hydroxycholesterol, markedly stimulated apoD release (by five- to 10-fold).	Oxysterols	95-104	apolipoprotein D	Mus musculus	0-4
9422368-8	1998	ApoD was found to be a secreted protein from cultured normal astrocytes and treatment with the oxysterol, 25-hydroxycholesterol, markedly stimulated apoD release (by five- to 10-fold).	Oxysterols	95-104	apolipoprotein D	Mus musculus	149-153
9422368-8	1998	ApoD was found to be a secreted protein from cultured normal astrocytes and treatment with the oxysterol, 25-hydroxycholesterol, markedly stimulated apoD release (by five- to 10-fold).	25-hydroxycholesterol	106-127	apolipoprotein D	Mus musculus	0-4
9422368-8	1998	ApoD was found to be a secreted protein from cultured normal astrocytes and treatment with the oxysterol, 25-hydroxycholesterol, markedly stimulated apoD release (by five- to 10-fold).	25-hydroxycholesterol	106-127	apolipoprotein D	Mus musculus	149-153
9422368-13	1998	These results reveal hitherto unrecognized defects in apoD metabolism in NPC that appear to be linked to the known defects in cholesterol homeostasis in this disorder.	Cholesterol	126-137	apolipoprotein D	Mus musculus	54-58